

Daniel E Bauer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/36802/publications.pdf>

Version: 2024-02-01

93
papers

8,685
citations

81743

39
h-index

54797

84
g-index

106
all docs

106
docs citations

106
times ranked

11143
citing authors

#	ARTICLE	IF	CITATIONS
1	CRISPResso2 provides accurate and rapid genome editing sequence analysis. <i>Nature Biotechnology</i> , 2019, 37, 224-226.	9.4	891
2	BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. <i>Nature</i> , 2015, 527, 192-197.	13.7	726
3	An Erythroid Enhancer of <i>BCL11A</i> Subject to Genetic Variation Determines Fetal Hemoglobin Level. <i>Science</i> , 2013, 342, 253-257.	6.0	518
4	Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. <i>Nature Biotechnology</i> , 2020, 38, 883-891.	9.4	502
5	Analyzing CRISPR genome-editing experiments with CRISPResso. <i>Nature Biotechnology</i> , 2016, 34, 695-697.	9.4	410
6	Highly efficient therapeutic gene editing of human hematopoietic stem cells. <i>Nature Medicine</i> , 2019, 25, 776-783.	15.2	344
7	Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch. <i>Cell</i> , 2018, 173, 430-442.e17.	13.5	328
8	An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities. <i>Nature Biotechnology</i> , 2018, 36, 977-982.	9.4	328
9	Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 5773-5779.	3.2	323
10	Characterization of Genomic Deletion Efficiency Mediated by Clustered Regularly Interspaced Palindromic Repeats (CRISPR)/Cas9 Nuclease System in Mammalian Cells*. <i>Journal of Biological Chemistry</i> , 2014, 289, 21312-21324.	1.6	309
11	Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin. <i>Science</i> , 2016, 351, 285-289.	6.0	260
12	Therapeutic base editing of human hematopoietic stem cells. <i>Nature Medicine</i> , 2020, 26, 535-541.	15.2	196
13	Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6518-6523.	3.3	189
14	Combinatorial Assembly of Developmental Stage-Specific Enhancers Controls Gene Expression Programs during Human Erythropoiesis. <i>Developmental Cell</i> , 2012, 23, 796-811.	3.1	183
15	Reawakening fetal hemoglobin: prospects for new therapies for the β -globin disorders. <i>Blood</i> , 2012, 120, 2945-2953.	0.6	154
16	Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. <i>Cancer</i> , 2016, 122, 3632-3640.	2.0	145
17	Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. <i>Blood</i> , 2016, 127, 839-848.	0.6	138
18	Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype. <i>Journal of Clinical Investigation</i> , 2016, 126, 3868-3878.	3.9	129

#	ARTICLE	IF	CITATIONS
19	Generation of Genomic Deletions in Mammalian Cell Lines via CRISPR/Cas9. <i>Journal of Visualized Experiments</i> , 2015, , e52118.	0.2	123
20	Functional footprinting of regulatory DNA. <i>Nature Methods</i> , 2015, 12, 927-930.	9.0	123
21	Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. <i>Blood Advances</i> , 2019, 3, 3379-3392.	2.5	121
22	Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies. <i>British Journal of Haematology</i> , 2018, 180, 630-643.	1.2	107
23	miRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction. <i>Molecular Therapy</i> , 2015, 23, 1465-1474.	3.7	101
24	Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS. <i>Cancer Cell</i> , 2018, 33, 386-400.e5.	7.7	99
25	Variant-aware saturating mutagenesis using multiple Cas9 nucleases identifies regulatory elements at trait-associated loci. <i>Nature Genetics</i> , 2017, 49, 625-634.	9.4	96
26	Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin. <i>Current Opinion in Genetics and Development</i> , 2015, 33, 62-70.	1.5	94
27	Update on fetal hemoglobin gene regulation in hemoglobinopathies. <i>Current Opinion in Pediatrics</i> , 2011, 23, 1-8.	1.0	92
28	Emerging Genetic Therapy for Sickle Cell Disease. <i>Annual Review of Medicine</i> , 2019, 70, 257-271.	5.0	90
29	Rational targeting of a NuRD subcomplex guided by comprehensive in situ mutagenesis. <i>Nature Genetics</i> , 2019, 51, 1149-1159.	9.4	83
30	EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. <i>Blood</i> , 2015, 126, 1930-1939.	0.6	76
31	Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies. <i>Lancet, The</i> , 2016, 387, 2554-2564.	6.3	73
32	CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML. <i>Nature Chemical Biology</i> , 2019, 15, 529-539.	3.9	71
33	Integrated design, execution, and analysis of arrayed and pooled CRISPR genome-editing experiments. <i>Nature Protocols</i> , 2018, 13, 946-986.	5.5	70
34	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. <i>Cancer Cell</i> , 2019, 35, 664-676.e7.	7.7	70
35	Editing aberrant splice sites efficiently restores $\hat{\beta}$ -globin expression in $\hat{\beta}$ -thalassemia. <i>Blood</i> , 2019, 133, 2255-2262.	0.6	57
36	Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells. <i>Cell Stem Cell</i> , 2020, 26, 896-909.e8.	5.2	57

#	ARTICLE	IF	CITATIONS
37	The mTORC1/4E-BP pathway coordinates hemoglobin production with <sc>L</sc>-leucine availability. <i>Science Signaling</i> , 2015, 8, ra34.	1.6	54
38	BCL11A enhancer-edited hematopoietic stem cells persist in rhesus monkeys without toxicity. <i>Journal of Clinical Investigation</i> , 2020, 130, 6677-6687.	3.9	54
39	Genome-wide association study of red blood cell traits in Hispanics/Latinos: The Hispanic Community Health Study/Study of Latinos. <i>PLoS Genetics</i> , 2017, 13, e1006760.	1.5	53
40	An erythroid-specific ATP2B4 enhancer mediates red blood cell hydration and malaria susceptibility. <i>Journal of Clinical Investigation</i> , 2017, 127, 3065-3074.	3.9	48
41	Transcription factor competition at the $\hat{\beta}$ -globin promoters controls hemoglobin switching. <i>Nature Genetics</i> , 2021, 53, 511-520.	9.4	43
42	Erythropoietin signaling regulates heme biosynthesis. <i>ELife</i> , 2017, 6, .	2.8	36
43	ZNF410 represses fetal globin by singular control of CHD4. <i>Nature Genetics</i> , 2021, 53, 719-728.	9.4	35
44	CRISPRO: identification of functional protein coding sequences based on genome editing dense mutagenesis. <i>Genome Biology</i> , 2018, 19, 169.	3.8	34
45	Strict in vivo specificity of the Bcl11a erythroid enhancer. <i>Blood</i> , 2016, 128, 2338-2342.	0.6	33
46	CRISPR-SURF: discovering regulatory elements by deconvolution of CRISPR tiling screen data. <i>Nature Methods</i> , 2018, 15, 992-993.	9.0	33
47	Quantitative assessment of timing, efficiency, specificity and genetic mosaicism of CRISPR/Cas9-mediated gene editing of hemoglobin beta gene in rhesus monkey embryos. <i>Human Molecular Genetics</i> , 2017, 26, 2678-2689.	1.4	32
48	Genetic therapies for sickle cell disease. <i>Seminars in Hematology</i> , 2018, 55, 76-86.	1.8	32
49	Editing GWAS: experimental approaches to dissect and exploit disease-associated genetic variation. <i>Genome Medicine</i> , 2021, 13, 41.	3.6	32
50	Growing and Genetically Manipulating Human Umbilical Cord Blood-Derived Erythroid Progenitor (HUDEP) Cell Lines. <i>Methods in Molecular Biology</i> , 2018, 1698, 275-284.	0.4	31
51	FAM210B is an erythropoietin target and regulates erythroid heme synthesis by controlling mitochondrial iron import and ferrochelatase activity. <i>Journal of Biological Chemistry</i> , 2018, 293, 19797-19811.	1.6	30
52	Clonal hematopoiesis in sickle cell disease. <i>Blood</i> , 2021, 138, 2148-2152.	0.6	29
53	Functional interrogation of non-coding DNA through CRISPR genome editing. <i>Methods</i> , 2017, 121-122, 118-129.	1.9	28
54	AmpUMI: design and analysis of unique molecular identifiers for deep amplicon sequencing. <i>Bioinformatics</i> , 2018, 34, i202-i210.	1.8	28

#	ARTICLE	IF	CITATIONS
55	Whole-genome sequencing association analysis of quantitative red blood cell phenotypes: The NHLBI TOPMed program. <i>American Journal of Human Genetics</i> , 2021, 108, 874-893.	2.6	28
56	14q32 and let-7 microRNAs regulate transcriptional networks in fetal and adult human erythroblasts. <i>Human Molecular Genetics</i> , 2018, 27, 1411-1420.	1.4	25
57	Common variants in signaling transcription-factor-binding sites drive phenotypic variability in red blood cell traits. <i>Nature Genetics</i> , 2020, 52, 1333-1345.	9.4	24
58	A genome editing primer for the hematologist. <i>Blood</i> , 2016, 127, 2525-2535.	0.6	23
59	Dissecting ELANE neutropenia pathogenicity by human HSC gene editing. <i>Cell Stem Cell</i> , 2021, 28, 833-845.e5.	5.2	23
60	End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. <i>Blood Advances</i> , 2019, 3, 4002-4020.	2.5	21
61	Hematopoietic stem cells develop in the absence of endothelial cadherin 5 expression. <i>Blood</i> , 2015, 126, 2811-2820.	0.6	20
62	Technical considerations for the use of CRISPR/Cas9 in hematology research. <i>Experimental Hematology</i> , 2017, 54, 4-11.	0.2	18
63	Forward genetic screen of human transposase genomic rearrangements. <i>BMC Genomics</i> , 2016, 17, 548.	1.2	13
64	Editing outside the body: Ex Vivo gene-modification for β^2 -hemoglobinopathy cellular therapy. <i>Molecular Therapy</i> , 2021, 29, 3163-3178.	3.7	12
65	Curative approaches for sickle cell disease: A review of allogeneic and autologous strategies. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 67, 155-168.	0.6	11
66	Development of a double shmiR lentivirus effectively targeting both BCL11A and ZNF410 for enhanced induction of fetal hemoglobin to treat β^2 -hemoglobinopathies. <i>Molecular Therapy</i> , 2022, 30, 2693-2708.	3.7	11
67	Gene Editing ELANE in Human Hematopoietic Stem and Progenitor Cells Reveals Disease Mechanisms and Therapeutic Strategies for Severe Congenital Neutropenia. <i>Blood</i> , 2019, 134, 3-3.	0.6	8
68	Optimization of Bcl11a Knockdown By miRNA Scaffold Embedded Shrnas Leading to Enhanced Induction of Fetal Hemoglobin in Erythroid Cells for the Treatment of Beta-Hemoglobinopathies. <i>Blood</i> , 2014, 124, 2150-2150.	0.6	8
69	Molecular analysis of the erythroid phenotype of a patient with BCL11A haploinsufficiency. <i>Blood Advances</i> , 2021, 5, 2339-2349.	2.5	7
70	Aggressive treatment and survival outcomes in <i>NUT</i> midline carcinoma (NMC) of the head and neck (HN).. <i>Journal of Clinical Oncology</i> , 2014, 32, 6057-6057.	0.8	7
71	Single-cell cloning of human T-cell lines reveals clonal variation in cell death responses to chemotherapeutics. <i>Cancer Genetics</i> , 2019, 237, 69-77.	0.2	6
72	Durable and Robust Fetal Globin Induction without Anemia in Rhesus Monkeys Following Autologous Hematopoietic Stem Cell Transplant with BCL11A Erythroid Enhancer Editing. <i>Blood</i> , 2019, 134, 4632-4632.	0.6	6

#	ARTICLE	IF	CITATIONS
73	DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling. PLoS ONE, 2022, 17, e0263829.	1.1	6
74	Motif-Raptor: a cell type-specific and transcription factor centric approach for post-GWAS prioritization of causal regulators. Bioinformatics, 2021, 37, 2103-2111.	1.8	5
75	Optimization of Nuclear Localization Signal Composition Improves CRISPR-Cas12a Editing Rates in Human Primary Cells. , 2022, 1, 271-284.		5
76	DrugThatGene: integrative analysis to streamline the identification of druggable genes, pathways and protein complexes from CRISPR screens. Bioinformatics, 2019, 35, 1981-1984.	1.8	3
77	Identification Of BCL11A Structure-Function Domains For Fetal Hemoglobin Silencing. Blood, 2013, 122, 435-435.	0.6	3
78	Highly Efficient Therapeutic Gene Editing of BCL11A enhancer in Human Hematopoietic Stem Cells from α -Hemoglobinopathy Patients for Fetal Hemoglobin Induction. Blood, 2018, 132, 3482-3482.	0.6	2
79	Getting Past HSC Security: Cyclosporine H Gives Lentiviruses an Entry Pass. Cell Stem Cell, 2018, 23, 775-776.	5.2	1
80	Hematopoietic SIN Lentiviral Micro RNA-Mediated Silencing of BCL11A: Pre-Clinical Evidence for a Sickle Cell Disease Gene-Therapy Trial. Blood, 2012, 120, 753-753.	0.6	1
81	Mitochondrial Protein Kinase A Regulates Heme Biosynthesis. Blood, 2015, 126, 271-271.	0.6	1
82	Genome-Wide CRISPR/Cas9 Screen Reveals That the Dcps Scavenger Decapping Enzyme Is Essential for AML Cell Survival. Blood, 2017, 130, 782-782.	0.6	1
83	Gene Therapy. Hematology/Oncology Clinics of North America, 2017, 31, xiii-xiv.	0.9	0
84	Production of foetal globin in adult monkeys. Nature Biomedical Engineering, 2019, 3, 857-859.	11.6	0
85	Functional Evaluation of HbF-Associated Region of BCL11A Locus. Blood, 2011, 118, 2148-2148.	0.6	0
86	Sideroflexin 4 Deficiency Results In An Erythroid Differentiation Defect. Blood, 2013, 122, 3417-3417.	0.6	0
87	An SCF-FBXW7 Ubiquitin Ligase Mediated Feedback Loop Facilitates GATA Factor Switching and Reinforces Commitment to Terminal Erythroid Maturation. Blood, 2014, 124, 245-245.	0.6	0
88	Erythroid Cells Adapt to L-Leucine Scarcity By Reducing Hemoglobin Production Via the mTORC1/4E-BP Pathway. Blood, 2014, 124, 2660-2660.	0.6	0
89	Hematopoietic Stem Cells Develop in the Absence of Endothelial Cadherin 5 Expression. Blood, 2015, 126, 1165-1165.	0.6	0
90	Transcriptional Signaling Centers Govern Human Erythropoiesis and Harbor Genetic Variations of Red Blood Cell Traits. Blood, 2018, 132, 1277-1277.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Rational Targeting of a NuRD Sub-Complex for Fetal Hemoglobin Induction Following Comprehensive in Situ Mutagenesis. Blood, 2018, 132, 2342-2342.	0.6	0
92	Human Genetic Diversity Alters Therapeutic Gene Editing Off-Target Outcomes. Blood, 2021, 138, 3993-3993.	0.6	0
93	ZNF410 Represses Fetal Globin By Devoted Control of CHD4/NuRD. Blood, 2020, 136, 1-1.	0.6	0